We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$121M
Cap. Flow
-$91.5M
Cap. Flow %
-33.22%
Top 10 Hldgs %
43.72%
Holding
87
New
14
Increased
18
Reduced
10
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$11.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$7.62M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.89M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$6.84M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$6.59M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$7.5M
2
BBIO icon
BridgeBio Pharma
BBIO
+$6.79M
3
XLRN
Acceleron Pharma
XLRN
+$6.08M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.72M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 75.01%
2 Financials 4.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFIB
76
DELISTED
Acutus Medical Inc
AFIB
– –
-200,000
Closed -$1.77M
NSTG
77
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-75,000
Closed -$3.6M
CELL
78
DELISTED
PhenomeX Inc. Common Stock
CELL
– –
-55,000
Closed -$1.08M
HARP
79
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-25,000
Closed -$1.98M
GBT
80
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-75,000
Closed -$1.91M
XLRN
81
DELISTED
Acceleron Pharma
XLRN
– –
-35,350
Closed -$6.08M
TRIL
82
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-200,000
Closed -$3.51M
SKINW
83
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
– –
-34,400
Closed -$498K
HZNP
84
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-15,000
Closed -$1.64M
BHVN
85
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-7,500
Closed -$1.04M
1 2 3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Affinity Asset Advisors held 87 positions worth $275M, down 30% from $396M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Affinity Asset Advisors withdrew a net $91.5M in Q4 2021, closing 32 positions and reducing 10 holdings. Its most notable exit was Ocular Therapeutix, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Protagonist Therapeutics worth $8.25M.

  • Affinity Asset Advisors's largest Q4 2021 buy was Protagonist Therapeutics: 241,119 shares worth $8.25M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q4 2021, an estimated $11.4M increase.
  • Affinity Asset Advisors's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $6.79M.
  • Affinity Asset Advisors fully exited Ocular Therapeutix in Q4 2021, selling an estimated $7.5M.
  • Affinity Asset Advisors's ten largest holdings make up 44% of its $275M portfolio in Q4 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 32 in Q4 2021.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $275M.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.